Clinical Trial

Specific Versus Empirical Anthelminthic Treatment in Eosinophilia

Study acronym: Eosinophilia
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
There are a few guidelines recommend about management of eosinophilia worldwide, most of guielines recommend a thorough history-taking and physical examination. Subsequently, investigations are requested based on suspected causes. In cases where parasite infection is suspected, particularly in developing countries, stool microscopy and serology are recommended. However, limitations such as low sensitivity of stool microscopy, the inconvenience of collecting multiple stool samples, and the high cost and unavailability of serology may arise. Consequently, some physicians opt for empiric anthelminthic regimens in managing eosinophilic patients, even without stool tests or if stool test results are normal. If subsequent complete blood count (CBC) results show a recovery of absolute eosinophil count, it is assumed that eosinophilia was caused by a parasite infection. While some studies demonstrate the efficacy and simplicity of this approach, there is a risk of overestimating parasite infection in eosinophilic patients, potential adverse drug reactions from unnecessary anthelminthic treatment, and the possibility of drug resistance due to inappropriate dosing. To address this gap, no study has yet compared the efficacy between specific anthelminthic treatment based on test results and empirical anthelminthic treatment in eosinophilic patients. Therefore, the investigators are conducting this study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-10; most recent amendment 2024-09-22.
Status change: Not Yet Recruiting → Recruiting 2024-09-22
Trial Details
NCT Number NCT06265870
Lead Sponsor Prince of Songkla University
Conditions Eosinophilia
Enrollment 700 participants
Start Date 2024-05-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-24